OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
Metrics to compare | 226950 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship226950PeersSector | |
---|---|---|---|---|
P/E Ratio | −23.1x | −9.3x | −0.5x | |
PEG Ratio | 0.21 | −0.11 | 0.00 | |
Price/Book | 41.4x | 2.9x | 2.6x | |
Price / LTM Sales | 178.3x | 14.6x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 43.4% | |
Fair Value Upside | Unlock | 12.0% | 7.1% | Unlock |